Cytokine secretion by human mesenchymal stem cells cocultured with damaged corneal epithelial cells

Joo Youn Oh1, Mee Kum Kim, Mi Sun Shin

  • 1Department of Ophthalmology, Seoul National University College of Medicine, 28 Yeongeon-dong, Chongno-gu, Seoul 110-744, Republic of Korea.

Cytokine
|February 19, 2009
PubMed

Insights

Mesenchymal stem cells (MSCs) modulate corneal inflammation and blood vessel growth. Cocultures revealed MSCs increase interleukin-6 and vascular endothelial growth factor, crucial for these processes.

Area of Science:

  • Ophthalmology
  • Stem Cell Biology
  • Immunology

Background:

  • Mesenchymal stem cells (MSCs) show therapeutic potential in corneal diseases.
  • Previous studies indicated MSCs reduce corneal inflammation and neovascularization via paracrine signaling.

Purpose of the Study:

  • To identify specific molecules responsible for MSC-mediated effects on corneal inflammation and neovascularization.
  • To analyze cytokine secretion profiles of MSCs in various co-culture conditions.

Main Methods:

  • Co-culturing human MSCs with human peripheral blood mononuclear cells (hPBMCs) and/or chemically-damaged human corneal epithelial cells (hCECs).
  • Analyzing cytokine secretion profiles, including interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), transforming growth factor-beta1 (TGF-beta1), matrix metalloproteinases (MMP-2, MMP-9), thrombospondin-1, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and IL-10.

Main Results:

  • MSC co-cultures with hCECs significantly increased IL-6 and VEGF secretion from MSCs.
  • Addition of hPBMCs further enhanced IL-6 and VEGF levels.
  • MSCs constitutively expressed TGF-beta1, MMP-2, and thrombospondin-1.
  • MSCs suppressed MMP-9 secretion by hCECs.

Conclusions:

  • The study identifies IL-6 and VEGF as key candidate molecules mediating MSCs' anti-inflammatory and anti-angiogenic effects in the cornea.
  • These findings provide insights into the molecular mechanisms of MSC-based therapies for corneal injuries.

Related Concept Videos

Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...